RT Journal Article
SR Electronic
T1 Adding Rigor to Biomarker Evaluations - EDRN Experience
JF Cancer Epidemiology Biomarkers & Prevention
JO Cancer Epidemiol Biomarkers Prev
FD American Association for Cancer Research
SP cebp.0240.2020
DO 10.1158/1055-9965.EPI-20-0240
A1 Feng, Ziding
A1 Pepe, Margaret S
YR 2020
UL http://cebp.aacrjournals.org/content/early/2020/11/10/1055-9965.EPI-20-0240.abstract
AB The cancer early detection biomarker field was, compared to the therapeutic arena, in its infancy when the Early Detection Research Network (EDRN) was initiated in 2000. The EDRN has played a crucial role in changing the culture and the ways people do biomarker studies.The EDRN proposed biomarker developmental guidelines and biomarker pivotal trial study design standards, created biomarker reference sets and functioned as a unbiased broker for the field, implemented the most rigorous blinding policy in biomarker field, developed an array of statistical and computational tools for early detection biomarker evaluations, and developed a multi-disciplinary team-science approach. We reviewed these contributions made by the EDRN and their impacts in bringing the field to more maturity. Challenges and opportunities on the future of cancer early detection biomarker translational research are discussed, particularly in strengthening biomarker discovery pipeline and conducting more efficient biomarker validation studies. EDRN's approach and success changed how the biomarker field does biomarker studies.